PFEPfizerSigning up patients
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-Resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 900 (planned)
- Started
- Oct 22, 2024
- Main results expected
- Sep 30, 2027
- Fully finished
- Nov 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression Free Survival (rPFS)
Measured over: Randomization up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06629779 · record last updated 2026-10-30 · checked 2026-11-09 15:36 UTC